Tobacco Industry 1 April 2026 - 22 April 2026

British American Tobacco Shares Rise After Morgan Stanley Makes BAT Its Top European Tobacco Pick
···

British American Tobacco Shares Rise After Morgan Stanley Makes BAT Its Top European Tobacco Pick

Shares of British American Tobacco p.l.c. climbed Friday, following a double upgrade from Morgan Stanley, which bumped the stock up to overweight and put it at the top of its European tobacco picks. The call lent new momentum to a trade focused less on volume, more on cash returns. Overweight, in broker lingo, signals expectations that the stock will outpace its peers or the broader benchmark. This shift is in focus as investors debate if BAT’s cash payouts are enough to counter years of cigarette decline and stricter nicotine regulations. Shares closed Friday at 4,302 pence, up 1.97%, making BAT a standout on the FTSE 100—where the benchmark dropped 0.75%.
April 25, 2026
Imperial Brands Buyback Rolls On as Market-Share Worries Hit the Tobacco Stock
····

Imperial Brands Buyback Rolls On as Market-Share Worries Hit the Tobacco Stock

Imperial Brands PLC kept its buyback wheels turning this week, snapping up 190,000 ordinary shares for cancellation on April 21—despite fresh selling pressure hitting the tobacco group’s London-listed stock. The Bristol-based company, behind Winston, Davidoff and Gauloises, paid an average price of 2,758.2776 pence per share, a regulatory filing showed. Timing’s crucial here. Buybacks and dividends have long anchored the Imperial Brands investment story, but with market-share momentum lagging in core cigarette segments and growth slowing in smoking alternatives, investors are questioning if cash returns alone are enough to compensate.
April 22, 2026
British American Tobacco’s Velo Push Hits FDA Delay as U.S. Nicotine Pouch Reviews Stall
···

British American Tobacco’s Velo Push Hits FDA Delay as U.S. Nicotine Pouch Reviews Stall

British American Tobacco’s attempt to ramp up Velo nicotine pouch sales in the U.S. has hit a snag with regulators. Reuters said Wednesday that the U.S. Food and Drug Administration still hasn’t signed off on multiple products under a fast-track process, which had been expected to wrap up decisions by end-2025. BAT’s applications remain in limbo. Timing is key for BAT right now. The company’s counting on its smoke-free lineup—nicotine pouches, vapes, heated-tobacco—to offset the drag from falling cigarette sales. Back in February, BAT flagged that 2026 results would probably arrive at the lower boundary of its medium-term growth targets, despite 2025 shaping up to hit the top end of its guidance.
April 1, 2026